RxDoctor Payments DataLook up a doctor →

Kevin Bush, PA

Physician Assistant · Albany, GANPI 1114913332

Payments from drug & device makers

$13,560in general payments, 2019–2025

Across 609 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Sanofi$1K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$981
  • Sun Pharmaceutical Industries Inc.$877
  • Lilly USA, LLC$792
  • plus $6K from 23 others

What the payments were for

  • Food & beverage$12,78394%
  • Education$7776%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,560 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$370,931
Medicare patients
981
Services billed
7,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast50$257,389
Humira(Cf) PenAdalimumab16$216,683
Dupixent PenDupilumab30$111,506
OpzeluraRuxolitinib Phosphate21$66,121
Dupixent SyringeDupilumab14$52,389
Clobetasol Propionate204$12,052
Metronidazole153$10,535
Fluocinonide209$7,141
Ketoconazole327$6,376
Clindamycin Phosphate182$6,221
Triamcinolone Acetonide385$6,190
Mupirocin694$5,199
Fluocinolone AcetonideFluocinolone/Shower Cap76$4,018
Ammonium Lactate233$3,925
Tacrolimus26$3,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$489$257,38950 claims
Incyte CorporationOpzelura$720$66,12121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →